Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ex-Merck Partner Symphogen Expects €67.5m To Burn A Hole In Its R&D Pocket

This article was originally published in Scrip

Executive Summary

If all goes to plan, Symphogen – the Danish biotechnology company developing antibody mixture therapies to treat cancer – expects to need more cash within a year, despite raising €67.5m via a convertible debt facility from existing investors this week. The round was led by Novo A/S and the Danish pension fund PKA.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register